Wells Fargo Maintains Equal-Weight on Nurix Therapeutics, Lowers Price Target to $20
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Derek Archila maintains Nurix Therapeutics (NASDAQ:NRIX) with a Equal-Weight and lowers the price target from $25 to $20.
Wells Fargo analyst Derek Archila maintains Nurix Therapeutics (NASDAQ:NRIX) with a Equal-Weight and lowers the price target from $25 to $20.